NCT05307198 (RAIC) is a Phase 2 clinical trial of Oxaliplatin in Rectal Neoplasms, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05307198?

NCT05307198 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT05307198?

Interventions in NCT05307198: Oxaliplatin, Rectectomy, Capecitabine, Anti-PD-1 monoclonal antibody.

What condition does NCT05307198 study?

NCT05307198 studies Rectal Neoplasms.

Is NCT05307198 still recruiting?

NCT05307198 is currently status unknown. Last updated 10 October 2023.

Last reviewed 2023-10-10 · How we verify

NCT05307198: RAIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC

Status unknown Phase 2 Last updated 10 October 2023

What this trial tests

Phase 2 trial testing Oxaliplatin in Rectal Neoplasms in 38 participants. Status unknown.

Timeline

11 May 2022

Primary endpoint
25 April 2024

25 April 2025

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	11 May 2022
Primary completion	25 April 2024
Estimated completion	25 April 2025
Sites	1 location across China

Drugs / interventions tested

Oxaliplatin (Oxaliplatin) — full drug profile →
Rectectomy
Capecitabine (capecitabine) — full drug profile →
Anti-PD-1 monoclonal antibody — full drug profile →

Conditions studied

Rectal Neoplasms — all drugs for Rectal Neoplasms →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 75, any sex, with Rectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore whether rectal artery infusion chemotherapy combined with anti-PD1 antibody is an effective neoadjuvant therapy for the microsatellite stable locally advanced rectal cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency.
Li Z, Lai X, Fu S, Ren L, et al · · 2022 · cited 407× · PMID 35652198 · DOI 10.1002/advs.202201734
Trial watch: chemotherapy-induced immunogenic cell death in oncology.
Sprooten J, Laureano RS, Vanmeerbeek I, Govaerts J, et al · · 2023 · cited 59× · PMID 37284695 · DOI 10.1080/2162402x.2023.2219591
Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy.
Wang Y, Zhu T, Shi Q, Zhu G, et al · · 2024 · cited 23× · PMID 38242718 · DOI 10.1136/jitc-2023-008026
Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot.
Han Y, Tian X, Zhai J, Zhang Z. · · 2024 · cited 20× · PMID 38774648 · DOI 10.3389/fcell.2024.1363121
Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy.
Wang J, Ma J, Xie F, Miao F, et al · · 2024 · cited 19× · PMID 38745666 · DOI 10.3389/fimmu.2024.1389173
Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation.
Fabian KP, Kowalczyk JT, Reynolds ST, Hodge JW. · · 2022 · cited 18× · PMID 36497086 · DOI 10.3390/cells11233826
Metal-based immunogenic cell death inducers for cancer immunotherapy.
Zou JX, Chang MR, Kuznetsov NA, Kee JX, et al · · 2025 · cited 12× · PMID 40160356 · DOI 10.1039/d4sc08495k
Combination immunotherapy for colorectal cancer: Clinical applications, rationale, challenges, and future perspectives.
Fei J, Cai C, Wu W, Shen H, et al · · 2026 · PMID 41950929 · DOI 10.1016/j.xcrm.2026.102728

Verify or expand the search:

Other trials of Oxaliplatin

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting

Other recruiting trials for Rectal Neoplasms

Currently open trials in the same condition.

NCT07522294 — Optimization and Standardization of Single-Port Robotic Transanal Minimally Invasive Surgery for Rectal Tumor Excision · NA · active not recruiting
NCT07154173 — Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer · recruiting
NCT06442215 — Selection of Surgical Technique in Rectal Cancer · recruiting
NCT06017583 — Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT05943444 — Comparison of Postoperative Anal Function Between Parks and Bacon Techniques in Low Rectal Cancer · NA · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05307198 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 10 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05307198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing